Q-omics provides the consensus-scored TMEM143 profile across patient tissues and cancer cell-line models. TMEM143 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM143 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, TMEM143 RNA expression shows 19,048 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRP, LIHC, and DLBC as cancer lineages where TMEM143 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM143 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM143 survival associations across molecular data types. TMEM143 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM143 RNA expression–survival associations across cancer types. High TMEM143 expression shows unfavorable associations in LGG, LUAD, THCA and UVM, but favorable associations in KIRP and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM143 RNA expression.
This table summarizes TMEM143 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 5. The strongest signals are observed in BRCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM143. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM143 shows lower tumor expression in THCA, BRCA, BLCA and HNSC and higher tumor expression in LIHC and COAD. The LIHC box plot shows higher TMEM143 RNA expression in tumor versus normal tissue (log2 FC = +0.637, t-test p < 0.001).
This table shows molecular features associated with TMEM143 in patient tissues and cancer cell lines. In patient samples, TMEM143 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM143 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
